Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

Literature DB >> 5081595

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

F M Muggia, P J Creaven, H H Hansen, M H Cohen, O S Selawry.

Abstract

Entities: Chemical

Mesh：

Substances：
Camptothecin

Year: 1972 PMID： 5081595

Source DB: PubMed Journal: Cancer Chemother Rep ISSN： 0069-0112

Keyword Cloud
Cited

× No keyword cloud information.

66 in total

Review 1. Camptothecin delivery methods.

Authors: A Hatefi; B Amsden
Journal: Pharm Res Date: 2002-10 Impact factor: 4.200

Review 2. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors: Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal: Am J Cancer Res Date: 2017-12-01 Impact factor: 6.166

Review 3. Targeting Topoisomerase I in the Era of Precision Medicine.

Authors: Anish Thomas; Yves Pommier
Journal: Clin Cancer Res Date: 2019-06-21 Impact factor: 12.531

4. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs.

Authors: E Merisko-Liversidge; P Sarpotdar; J Bruno; S Hajj; L Wei; N Peltier; J Rake; J M Shaw; S Pugh; L Polin; J Jones; T Corbett; E Cooper; G G Liversidge
Journal: Pharm Res Date: 1996-02 Impact factor: 4.200

5. Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives.

Authors: Guillermo Rodriguez-Berna; Maria Jose Díaz Cabañas; Victor Mangas-Sanjuán; Marta Gonzalez-Alvarez; Isabel Gonzalez-Alvarez; Ibane Abasolo; Simó Schwartz; Marival Bermejo; Avelino Corma
Journal: ACS Med Chem Lett Date: 2013-05-28 Impact factor: 4.345

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

Review 1. Camptothecin delivery methods.

Review 2. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Review 3. Targeting Topoisomerase I in the Era of Precision Medicine.

4. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs.

5. Semisynthesis, cytotoxic activity, and oral availability of new lipophilic 9-substituted camptothecin derivatives.

6. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.

7. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice.

8. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas.

9. Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats.

Review 10. Clinical pharmacokinetics of topotecan.